Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbVie pays a higher 2.78% yield but relies heavily on immunology drugs like Skyrizi and Rinvoq, facing risks from product concentration and recent acquisitions. Investors favor J&J for stable income and AbbVie for growth potential amid its post-Humira transition and strategic acquisitions.
Three dividend stocks—Johnson & Johnson, Realty Income, and JPMorgan Chase—are highlighted as strong retirement investments due to their reliable and growing payouts. Johnson & Johnson boasts a 64-year streak of dividend increases supported by accele...
PepsiCo announced that Joaquin Duato, Chairman and CEO of Johnson & Johnson, will join its Board of Directors as an independent member effective December 1, 2026. Duato will serve on the Audit Committee, bringing over three decades of leadership expe...
